Xenetic Biosciences Extends Collaboration with Scripps Research

Xenetic Biosciences, Inc. has announced a four-month extension of its research and development collaboration with Scripps Research. This partnership aims to further advance the company’s innovative DNase platform, which focuses on enhancing immuno-oncology technologies for the treatment of challenging cancers. The extension, confirmed in a statement on November 19, 2025, reflects the commitment of both organizations to push the boundaries of cancer treatment.

The collaboration with Scripps Research, a renowned institution in biomedical research, allows Xenetic to leverage cutting-edge scientific expertise. The work will primarily focus on optimizing the DNase platform, which has shown promise in addressing some of the most difficult-to-treat cancers. By deepening this partnership, Xenetic aims to accelerate the development of new therapeutic options for patients in need.

Xenetic’s Chief Executive Officer, Jeffrey D. Eisenberg, expressed enthusiasm about the extension, stating that the collaboration has already yielded significant advancements. “We believe that our ongoing work with Scripps Research will lead to breakthrough therapies that can make a meaningful impact in the fight against cancer,” Eisenberg noted.

As part of this initiative, the companies will engage in comprehensive research activities over the next four months. This includes refining the DNase technology and conducting preclinical studies to assess its efficacy. The goal is to advance these findings toward potential clinical applications, ultimately bringing new hope to patients battling cancer.

Xenetic Biosciences is committed to developing innovative solutions that address unmet medical needs in oncology. The company has a strong pipeline of products and is focused on technologies that enhance the body’s immune response to cancer cells. The extended collaboration with Scripps Research is pivotal for Xenetic as it seeks to position itself at the forefront of biopharmaceutical advancements.

The partnership not only underscores Xenetic’s dedication to innovation but also highlights the importance of collaboration in scientific research. By working alongside leading experts at Scripps Research, Xenetic is well-equipped to navigate the complexities of drug development and bring transformative therapies to market.

With the healthcare landscape continually evolving, this collaboration represents a strategic move for Xenetic Biosciences as it strives to enhance its research capabilities and expand its influence in the competitive biopharmaceutical industry. The coming months will be critical as both organizations work together to achieve their shared goal of advancing cancer treatment through innovative science.